TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04676607
Drug: SHR7390
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7390
Study: NCT03922815
Drug: rescue fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a rescue dose of fentanyl 0,5 mcg per kilogram of body
Study: NCT04469023
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
Study: NCT03781700
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
Study: NCT04179890
Drug: Afatinib (Gi(l)otrif®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Study: NCT04179890
Drug: Afatinib (Gi(l)otrif®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As first line therapy.
Study: NCT00095238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Study: NCT02011516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00677170
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
Study: NCT04005716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
Study: NCT01348659
Drug: 7.2% NaCl/hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
Study: NCT01348659
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
Study: NCT02856126
Drug: TACE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
Study: NCT02856126
Drug: HAIC Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Study: NCT02457273
Drug: TLC 388
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
Study: NCT00872027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills for 8 weeks
Study: NCT03169660
Drug: Vascular endothelial growth factor trap-eye
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
Study: NCT02072174
Drug: Anaferon for Children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaferon for children: For oral use.
Study: NCT00768157
Drug: antiviral treatment (lamivudine or entecavir)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
Study: NCT02348905
Drug: ACTHAR Gel 80 units twice weekly.
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
Study: NCT01747044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03486223
Drug: GSK2256294
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be taken daily by mouth for 7 days.
Study: NCT03486223
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken daily by mouth for 7 days.
Study: NCT00822783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01749137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous infusion
Study: NCT01572558
Drug: Conservative, non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
Study: NCT02826902
Drug: propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
Study: NCT02826902
Drug: desflurane and remifentanil
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is induced and maintained with desflurane and remifentanil
Study: NCT01758432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02298920
Drug: AZD0914
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
Study: NCT03198572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
Study: NCT00933972
Drug: RO4998452
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg po single dose
Study: NCT00793091
Drug: C-KAD Ophthalmic Solution
Normalized name: urea c-13 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops applied daily for 120 days
Study: NCT00793091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops applied daily for 120 days
Study: NCT00680017
Drug: ABT-335 plus rosuvastatin
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
Study: NCT00680017
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
Study: NCT02288377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03976349
Drug: BIIB094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03511963
Drug: HLX04 100 mg in 4 ml Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
Study: NCT03511963
Drug: Avastin 100 mg in 4 ml Injection
Normalized name: Avastin 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
Study: NCT00709735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching propranolol) short-acting and long-acting capsules
Study: NCT03584373
Drug: Ketorolac Oral Tablet [Toradol]
Normalized name: ketorolac Oral Tablet [Toradol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
Study: NCT03584373
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
Study: NCT03584373
Drug: Oxycodone Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
Study: NCT01701674
Drug: Cyclophosphamide as Part of Lymphodepletion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00084591
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02285452
Drug: Zingiberis Rhizoma plv.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02285452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04341207
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
Study: NCT01455129
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, once daily, inhaled by HandiHaler
Study: NCT02691598
Drug: Infusion
Normalized name: INFUSION SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
Study: NCT02677324
Drug: ABT199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCL-2 antagonist
Study: NCT01895361
Drug: SelG1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01895361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04169373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for upadacitinib tablet administered orally
Study: NCT01883531
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PLacebo is non respirable mannitol due to the big size particle
Study: NCT04143711
Drug: DF1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy agent targeting NK cells.
Study: NCT01248611
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nasally, dose titrated to effect
Study: NCT02273609
Drug: Vitamin K antagonists (acenocoumarol or warfarin)
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor.
Study: NCT02402842
Drug: Docetaxel, Cisplatin and 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
Study: NCT03573102
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor once daily
Study: NCT00091507
Drug: GIK
Normalized name: Surgikos Tip Cleaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
Study: NCT00091507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
Study: NCT04811911
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study: NCT03583242
Drug: Antiangiogenic Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Study: NCT03583242
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Study: NCT03607656
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablet
Study: NCT04025476
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and oral steroids
Study: NCT00351078
Drug: PTC124
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
Study: NCT00879931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%)
Study: NCT02671162
Drug: Fumaria
Normalized name: Fumaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day each time 2 capsules before eating meal for 8 weeks.
Study: NCT00277641
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical tablets to study drug
Study: NCT00420641
Drug: GSK372475
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK372475 1.0-1.5 mg/day
Study: NCT03333668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (10mg) tablet
Study: NCT05484687
Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 1.5 mg/kg lidocaine
Study: NCT04345887
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x100 mg spironolactone for 5 consecutive days
Study: NCT04345887
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x1 placebo tablet
Study: NCT03562377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT02937662
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
Study: NCT02937662
Drug: Physician-Directed Regimens without Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
Study: NCT00005893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01222559
Drug: co.don chondrosphere®
Approvals — FDA: no, EMA: no, PMDA: no
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
Study: NCT04038346
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to an NSAID (naproxen)
Study: NCT04038346
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to acetaminophen
Study: NCT02121405
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
Study: NCT02120456
Drug: LEO 43204
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02120456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741429
Drug: Technosphere Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects previously treated with Technosphere Insulin Inhalation Powder
Study: NCT00741429
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects previously treated with other anti-diabetic medications
Study: NCT00582816
Drug: conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
Study: NCT03210688
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet prednisolone
Study: NCT03422796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT03118518
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug initiation
Study: NCT04529096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01079702
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
Study: NCT01710371
Drug: 10% Arginine Hydrochloride-R-Gene 10
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00065559
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02217527
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
Study: NCT01722227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01039584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal cream
Study: NCT03133065
Drug: treatment of HCV with oral direct acting antiviral therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
Study: NCT01039584
Drug: Gynazole 1 vaginal cream
Normalized name: Gynazole-1 Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal cream
Study: NCT04266301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
Study: NCT04078659
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Study: NCT05391893
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
Study: NCT03169790
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03169790
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT03906695
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral decitabine 5mg + cedazuridine
Study: NCT03906695
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral decitabine 10mg + cedazuridine
Study: NCT02078973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Unikalk pr day for 1 day
Study: NCT02548728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
Study: NCT01476345
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT02328469
Drug: symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
Study: NCT00923728
Drug: AVN944
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03945760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02328469
Drug: Ceftriaxone or Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
Study: NCT00568776
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELND005 matched placebo capsules for oral administration, bid for 78 weeks